Further evidence that fibrillar collagen is unable to promote platelet shape change and aggregation in the absence of secondary agonists

Abstract

pation of ADP and TxA2 (5,7 among the others). Finally, we agree that the P2Y 1 receptor might, in combination with aspirin, be a promising target for future pharmacological approaches, as we believe that reducing platelet aggregation is far more important than reducing platelet shape change in the prevention of thrombus formation. However, we disagree with the statement it would appear more advantageous to improve pharmacological targeting of secondary agonist pathways rather than collagen receptors themselves, as at present there is not enough experimental evidence in this regard. We therefore consider this final assertion of Ohlmann et al. [1] to be highly speculative and wish to state categorically that neither challenging the role of ADP receptor antagonists nor suggesting the utility of collagen receptor inhibitors was the